HB 3799 — Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration.
Last action — In House Committee
-
✓Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill is in committee in the House. Introduced March 05, 2025. It must pass committee before a floor vote.
Next likely step: a committee vote, then a floor vote in the House.
Odds of enactment
Low chanceBased on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
In Committee
Current position in the legislative process.
-
2 sponsors
1 primary, 1 co-sponsors signed on.
-
Bipartisan support
Sponsored across 2 parties (1 D · 1 R) — cross-party backing.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
Summary
Digest: The Act allows doctors to give some patients novel types of treatment. (Flesch Readability Score: 74.8). Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration. Provides protections, including a waiver of liability, for health care practitioners, health care facilities, professional organizations or associations and manufacturers or distributors of investigational products that comply with the Act.
Bill Text
We don't have the full text on file for this bill yet.
Read HB 3799 on the official Oregon source →Action History
-
In House Committee
Sponsors
- Ben Bowman · Primary
- Ed Diehl · Cosponsor
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 1 co-sponsors · 88 not signed on
Sponsors (1)
- Ben Bowman Democrat
Co-sponsors (1)
- Ed Diehl Republican
Not signed on (88)
88 members have not signed on to this bill.
Show all 88 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HB 3799 do?
- Digest: The Act allows doctors to give some patients novel types of treatment. (Flesch Readability Score: 74.8). Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration. Provides protections, including a waiver of liability, for health care practitioners, health care facilities, professional organizations or associations and manufacturers or distributors of investigational products that comply with the Act.
- Who sponsors HB 3799?
- HB 3799 is sponsored by Ben Bowman (Democrat) and Ed Diehl (Republican).
- What is the current status of HB 3799?
- This bill is in committee in the House. Introduced March 05, 2025. It must pass committee before a floor vote.
- Where can I track HB 3799?
- Track HB 3799 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB 3799
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB 3799
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →